Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

29 Aug 2014
Price Change (% chg)

$0.23 (+0.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for INCY.OQ


Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the... (more)


Beta: 1.19
Market Cap (Mil.): $9,084.14
Shares Outstanding (Mil.): 168.41
Dividend: --
Yield (%): --


  INCY.OQ Industry Sector
P/E (TTM): -- 154.38 33.56
EPS (TTM): -0.83 -- --
ROI: -34.03 -3.22 17.31
ROE: -- -7.68 18.05
Search Stocks

AstraZeneca and Incyte to study cancer drugs together

LONDON, May 14 - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte , highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.

14 May 2014


  Price Change
Pfizer Inc. (PFE.N) $29.42 +0.04
Abbott Laboratories (ABT.N) $42.15 -0.20
Amgen, Inc. (AMGN.OQ) $138.83 +0.14
Biogen Idec Inc (BIIB.OQ) $340.02 -1.22
Array Biopharma Inc (ARRY.OQ) $3.90 +0.03

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks